We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The therapeutic potential of Ma'aljobon, a whey product, in primary hypertension: A double-blind randomized controlled trial.
- Authors
Shojaii, Asie; Ghods, Roshanak; Hashem-Dabaghian, Fataneh; Navabzadeh, Maryam; Kazemi, Tooba; Weyers, Morné; Matsabisa, Motlalepula G.
- Abstract
Objective: Ma'aljobon is used in Persian medicine (PM) as a natural antihypertensive product. This study aimed to evaluate the hypotensive effect of Ma'aljobon in patients with uncontrolled grade 1 primary hypertension (HTN). Materials and Methods: This double-blind, placebo-controlled clinical trial included 114 patients (20-80 years) with uncontrolled grade 1 primary HTN. After obtaining informed consent, the participants were randomly divided into two groups and administered with 25g of Ma'aljobon or maltodextrin twice daily for six weeks. Systolic and diastolic blood pressures (SBP and DBP, respectively) were analyzed. Results: A total of 97 patients (52.3±10.7 years, S.6 female) completed the study. In the Ma'aljobon group, SBP decreased from 150.3±12.3 to 130.6±12.1 mm Hg, and DBP decreased from 93.3±8.2 to 80.1±6.6 mm Hg (p<0.001). In the control group, SBP decreased from 147.6±11.2 to 138.7±14.4 mm Hg, and DBP decreased from 86.6±7.7 to 82.2±8.2 mm Hg (p<0.001). There was a significant difference in the changes of SBP and DBP between the two groups over time (p<0.001). No adverse events were observed. Conclusion: Ma'aljobon has a stronger hypotensive effect than placebo in patients with HTN and can be recommended as an addon therapy for uncontrolled HTN.
- Subjects
DIASTOLIC blood pressure; ESSENTIAL hypertension; SYSTOLIC blood pressure; WHEY products; WHEY proteins
- Publication
Avicenna Journal of Phytomedicine, 2025, Vol 15, Issue 1, p848
- ISSN
2228-7930
- Publication type
Academic Journal
- DOI
10.22038/AJP.2024.24921